GlassScriptPhysician profile
William Thad Poisson
NPI 1447603949
$1,536.48
in general payments reported to CMS, 2019-2025
22 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $277 · 2022: $323 · 2023: $305 · 2024: $481 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $936.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $335.87 | 2021-2024 | Farxiga |
| Fresenius USA Marketing, INC. | $210.73 | 2022-2024 | Velphoro, Korsuva |
| Ardelyx, INC. | $136.39 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Amgen INC. | $126.62 | 2021-2022 | |
| Vifor Pharma, INC. | $101.55 | 2021-2025 | Veltassa |
| Mallinckrodt Hospital Products INC. | $78.69 | 2022-2025 | Acthar |
| Otsuka America Pharmaceutical, INC. | $76.43 | 2023-2025 | Jynarque |
| Glaxosmithkline, LLC. | $76.41 | 2022-2023 | Jesduvroq, Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $65.00 | 2021-2024 | |
| Aurinia Pharma U.S., INC. | $40.14 | 2021-2024 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $35.37 | 2022-2024 | Ultomiris |
| Lexicon Pharmaceuticals, INC. | $35.16 | 2023 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.72 | 2022 | |
| Novartis Pharmaceuticals Corporation | $28.10 | 2024 | |
| Merck Sharp & Dohme LLC | $26.21 | 2025 | Prevymis |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $24.04 | 2022 | |
| Renalytix Ai, INC. | $20.12 | 2022 | |
| Veloxis Pharmaceuticals, INC. | $19.08 | 2024 | Envarsus |
| Opko Pharmaceuticals, LLC | $18.04 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.90 | 2025 | |
| Travere Therapeutics, INC. | $16.88 | 2025 | |
| Mylan Specialty L.P. | $14.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Poisson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.